Connect Biopharma presented clinical data supporting rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress. The data continues to demonstrate the potential of rademikibart to deliver best-in-class efficacy for asthma patients.
The analyses highlighted rademikibart’s capability to rapidly deliver improvements in lung function and significantly reduce annualized asthma exacerbation rates. These effects were particularly noted in patients with high eosinophil and fractional exhaled nitric oxide (FeNO) counts, which are key markers of type 2 inflammation.
These findings build on previously reported data from the Phase 2b asthma study and bolster support for the rapid Phase 2 clinical development plan. Topline data from the parallel Seabreeze STAT studies are expected in the first half of 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.